 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...192193194195196197198199200201202...208209» |
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Trial withdrawal: ATinPC: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 12, 2018
P=N/A, N=0, Withdrawn, Sponsor: Changzhou No.2 People's Hospital
Not yet recruiting --> Withdrawn | N=30 --> 0
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC (clinicaltrials.gov) - Sep 12, 2018
P2, N=50, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: CameL-sq: A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC (clinicaltrials.gov) - Sep 12, 2018
P3, N=360, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | edralbrutinib (TG-1701) / TG Therap
New P1 trial: Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers (clinicaltrials.gov) - Sep 12, 2018
P1, N=30, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial completion date, Trial initiation date, PD(L)-1 Biomarker, IO biomarker: A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Sep 11, 2018
P2, N=120, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Withdrawn | N=30 --> 0 Active, not recruiting --> Recruiting | Trial completion date: Oct 2018 --> Jun 2019 | Initiation date: Jan 2017 --> Jun 2017
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, PD(L)-1 Biomarker, IO biomarker: A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (clinicaltrials.gov) - Sep 11, 2018
P3, N=412, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Recruiting | Trial completion date: Oct 2018 --> Jun 2019 | Initiation date: Jan 2017 --> Jun 2017 Trial completion date: Jun 2019 --> Dec 2019
- | edralbrutinib (TG-1701) / TG Therap
New P1 trial: Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor (clinicaltrials.gov) - Sep 9, 2018
P1, N=90, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / BMS, plinabulin (BPI 2358) / BeyondSpring
Enrollment open: BTCRC-LUN17-127: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov) - Sep 7, 2018
P1/2, N=55, Recruiting, Sponsor: Jyoti Malhotra
Trial completion date: Jun 2019 --> Dec 2019 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors (clinicaltrials.gov) - Sep 7, 2018
P2, N=25, Completed, Sponsor: Rongjie Tao
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date, Trial primary completion date: XHZL: Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2018
P2, N=50, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
Not yet recruiting --> Recruiting Initiation date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Trial primary completion date: APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) - Sep 5, 2018
P2, N=43, Active, not recruiting, Sponsor: Peking University People's Hospital
Initiation date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Sep 2018
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P1/2 trial, Metastases: Y-HR2017-025: Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies (clinicaltrials.gov) - Aug 31, 2018
P1/2, N=30, Not yet recruiting, Sponsor: China International Medical Foundation
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Combination therapy: This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment (clinicaltrials.gov) - Aug 29, 2018
P2, N=60, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P3 trial: Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer (clinicaltrials.gov) - Aug 29, 2018
P3, N=90, Not yet recruiting, Sponsor: Beijing Chest Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P1 trial, New P2 trial: Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 29, 2018
P1, N=32, Recruiting, Sponsor: Yongchang Zhang, MD
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: CAPTAIN: SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. (clinicaltrials.gov) - Aug 24, 2018
P2, N=155, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Sep 2018 Not yet recruiting --> Recruiting
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Enrollment open: CHART: A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Aug 24, 2018
P3, N=572, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 23, 2018
P2, N=135, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P1 trial, PARP Biomarker, Metastases: Treatment of Carrying TP53 Harmful Mutations (clinicaltrials.gov) - Aug 23, 2018
P1, N=60, Not yet recruiting, Sponsor: Tianjin Medical University Second Hospital
- | SHR0532 / Jiangsu Hengrui Pharma
New P1 trial: The PK/PD Study of SHR0532 Tablets in Healthy Subjects (clinicaltrials.gov) - Aug 23, 2018
P1, N=50, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | gefitinib / Generic mfg.
Enrollment open, Enrollment change: Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (clinicaltrials.gov) - Aug 21, 2018
P2, N=300, Recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=150 --> 300
- | otesaconazole (VT-1161) / Mycovia Pharma
Enrollment open: VIOLET: A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Aug 20, 2018
P3, N=300, Recruiting, Sponsor: Mycovia Pharmaceuticals Inc.
Not yet recruiting --> Recruiting | N=150 --> 300 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New trial: A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=80, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P1 trial: The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects (clinicaltrials.gov) - Aug 15, 2018
P1, N=32, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neo-PLANET: Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (clinicaltrials.gov) - Aug 14, 2018
P2, N=36, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P4 trial: Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (clinicaltrials.gov) - Aug 14, 2018
P4, N=100, Recruiting, Sponsor: Zhengzhou University
- | AiTan (rivoceranib) / HLB Bio Group
New trial, Metastases: Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib (clinicaltrials.gov) - Aug 13, 2018
P=N/A, N=187, Completed, Sponsor: The Affiliated Hospital of Qingdao University
- | zeprumetostat (SHR-2554) / Treeline Biosci
Enrollment open: A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (clinicaltrials.gov) - Aug 8, 2018
P1, N=42, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer (clinicaltrials.gov) - Aug 7, 2018
P2, N=30, Recruiting, Sponsor: Chinese Academy of Medical Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Enrollment open: A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics (clinicaltrials.gov) - Aug 2, 2018
P1, N=15, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Aug 1, 2018
P2, N=240, Recruiting, Sponsor: Wei Jiang
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma (clinicaltrials.gov) - Aug 1, 2018
P2, N=40, Not yet recruiting, Sponsor: First Affiliated Hospital of Guangxi Medical University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. (clinicaltrials.gov) - Jul 29, 2018
P3, N=448, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer (clinicaltrials.gov) - Jul 26, 2018
P2, N=30, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P1 trial: A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics (clinicaltrials.gov) - Jul 26, 2018
P1, N=15, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | zeprumetostat (SHR-2554) / Treeline Biosci
New P1 trial: A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (clinicaltrials.gov) - Jul 26, 2018
P1, N=42, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial completion date, Trial primary completion date: A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC (clinicaltrials.gov) - Jul 26, 2018
P2, N=152, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting N=36 --> 152 | Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Nov 2018
- | AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial, Metastases: XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma (clinicaltrials.gov) - Jul 26, 2018
P1/2, N=52, Not yet recruiting, Sponsor: Anhui Provincial Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P1/2 trial: A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC (clinicaltrials.gov) - Jul 25, 2018
P1/2, N=41, Not yet recruiting, Sponsor: Harbin Medical University
- | plinabulin (BPI 2358) / BeyondSpring
Trial completion date, Trial primary completion date: Protective-1: Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (clinicaltrials.gov) - Jul 24, 2018
P2/3, N=170, Recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
N=36 --> 152 | Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Nov 2018 Trial completion date: Jun 2018 --> May 2019 | Trial primary completion date: Mar 2018 --> Jan 2019
- | SHR9549 / Jiangsu Hengrui Pharma
New P1 trial: SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Jul 24, 2018
P1, N=44, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC (clinicaltrials.gov) - Jul 22, 2018
P2, N=42, Recruiting, Sponsor: Shandong Cancer Hospital and Institute
Trial completion date: Jun 2018 --> May 2019 | Trial primary completion date: Mar 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New trial, Real-world evidence, Real-world: Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration?A Real World Exploratory Study (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=31, Not yet recruiting, Sponsor: Beijing Chest Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open: PHEDRA: Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer (clinicaltrials.gov) - Jul 19, 2018
P3, N=294, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Platinum resistant: Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 19, 2018
P2, N=40, Recruiting, Sponsor: First Affiliated Hospital of Harbin Medical University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P3 trial: PHEDRA: Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer (clinicaltrials.gov) - Jul 16, 2018
P3, N=294, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Platinum resistant: Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 15, 2018
P2, N=40, Not yet recruiting, Sponsor: First Affiliated Hospital of Harbin Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P2/3 trial: Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer (clinicaltrials.gov) - Jul 15, 2018
P2/3, N=200, Enrolling by invitation, Sponsor: Hebei Medical University Fourth Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion date, Trial primary completion date, Metastases: ANGEL: A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (clinicaltrials.gov) - Jul 12, 2018
P3, N=459, Recruiting, Sponsor: LSK BioPartners Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Aug 2018 --> Feb 2019
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment closed, Metastases: A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment (clinicaltrials.gov) - Jul 11, 2018
P1, N=6, Active, not recruiting, Sponsor: Bukwang Pharmaceutical
Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Aug 2018 --> Feb 2019 Recruiting --> Active, not recruiting